Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19

Juan G. Ripoll^{1*}, MD, Sidna M. Tulledge-Scheitel^{2*}, MD, MPH, Anthony A. Stephenson¹, MD, Shane Ford¹, BS, Marsha L. Pike³, APRN, CNS, DNP, Ellen K. Gorman¹, BS, Sara N. Hanson⁴, DO, MPH, Justin E. Juskewitch⁵, MD, PhD, Alex J. Miller¹, BS, Solomiia Zaremba¹, MD, Erik A. Ovrom¹, BA, Raymund R. Razonable⁶, MD, Ravindra Ganesh⁷, MBBS, MD, Ryan T. Hurt⁷, MD, PhD, Erin N. Fischer³, MS, RN, Amber N. Derr⁸, MBA, Michele R. Eberle⁹, Jennifer J. Larsen⁸, MSN, RN, Christina M. Carney¹⁰, APRN, CNP, DNP, Elitza S. Theel⁵, PhD, Sameer A. Parikh¹¹, MBBS, Neil E. Kay^{11,12}, MD, Michael J. Joyner^{1,13†}, MD, and Jonathon W. Senefeld^{1,13,14}, PhD

AFFILIATIONS

- 1 | Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota
- 2 | Division of Community Internal Medicine, Mayo Clinic, Rochester, Minnesota
- 3 | Department of Nursing, Mayo Clinic, Rochester, Minnesota
- 4 | Department of Family Medicine, Mayo Clinic Health Care System, Mankato, Minnesota
- 5 | Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
- **6** | Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, Minnesota
- 7 | Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota
- 8 | Division of Hematology and Infusion Therapy, Rochester, Minnesota, USA
- 9 | Mayo Clinic Health System Northwest Wisconsin, Eau Claire, Wisconsin, USA
- 10 | Mayo Clinic Health System, Red Wing, Minnesota,
- 11 Division of Hematology, Mayo Clinic, Rochester, Minnesota
- 12 | Department of Immunology, Mayo Clinic, Rochester, Minnesota
- 13 | Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota
- **14** | Department of Health and Kinesiology, University of Illinois at Urbana-Champaign, Urbana, Illinois

²Correspondence:

Jonathon W. Senefeld, PhD, Department of Health and Kinesiology University of Illinois Urbana-Champaign | 906 S Goodwin | Urbana, Illinois 61801 senefeld@illinois.edu | 217-300-7991

†Drs. Joyner and Senefeld contributed equally as senior authors to the work of the study and manuscript.

^{*}Dr. Ripoll and Dr. Tulledge-Scheitel contributed equally as first authors to the work of the study and manuscript.

ABSTRACT

1

2

3

4

5

6

7

8

9

10

11

1213

14

15

16 17

18 19

20

21

22

23

24

25

26

27

28 29

30

31

Although severe coronavirus disease 2019 (COVID-19) and hospitalization associated with COVID-19 are generally preventable among healthy vaccine recipients, patients with immunosuppression have poor immunogenic responses to COVID-19 vaccines and remain at high risk of infection with SARS-CoV-2 and hospitalization. Additionally, monoclonal antibody therapy is limited by the emergence of novel SARS-CoV-2 variants that have serially escaped neutralization. In this context, there is interest in understanding the clinical benefit associated with COVID-19 convalescent plasma collected from persons who have been both naturally infected with SARS-CoV-2 and vaccinated against SARS-CoV-2 ("vax-plasma"). Thus, we report the clinical outcome of 386 immunocompromised outpatients who were diagnosed with COVID-19 and who received contemporary COVID-19 specific therapeutics (standard of care group) and a subgroup who also received concomitant treatment with very high titer COVID-19 convalescent plasma (vax-plasma group) with a specific focus on hospitalization rates. The overall hospitalization rate was 2.2% (5 of 225 patients) in the vax-plasma group and 6.2% (10 of 161 patients) in the standard of care group, which corresponded to a relative risk reduction of 65% (P=0.046). Evidence of efficacy in nonvaccinated patients cannot be inferred from these data because 94% (361 of 386 patients) of patients were vaccinated. In vaccinated patients with immunosuppression and COVID-19, the addition of vax-plasma or very high titer COVID-19 convalescent plasma to COVID-19 specific therapies reduced the risk of disease progression leading to hospitalization.

IMPORTANCE

As SARS-CoV-2 evolves, new variants of concern (VOCs) have emerged which evade available anti-spike monoclonal antibodies, particularly among immunosuppressed patients. However, high-titer COVID-19 convalescent plasma continues to be effective against VOCs because of its broad-spectrum immunomodulatory properties. Thus, we report clinical outcomes of 386 immunocompromised outpatients who were treated with COVID-19 specific therapeutics and a subgroup also treated with vaccine-boosted convalescent plasma. We found that administration of vaccine-boosted convalescent plasma was associated with a significantly decreased incidence of hospitalization among immunocompromised COVID-19 outpatients. Our data add to the contemporary data providing evidence to support the clinical utility of high-titer convalescent plasma as antibody replacement therapy in immunocompromised patients.

Introduction

32

3334

35

36

37

38

39

40

41

42 43

44 45

46

47

48

49

50

51

52 53

54

55

56

57

58

59 60

61

Although severe coronavirus disease 2019 (COVID-19) and hospitalization associated with COVID-19 are generally preventable among healthy vaccine recipients, patients with immunosuppression have poor immunogenic responses to COVID-19 vaccines and remain at high risk of infection with SARS-CoV-2 and hospitalization. 1,2 Passive antibody therapy, via monoclonal antibody therapy or COVID-19 convalescent plasma, has been widely used to treat COVID-19, particularly among patients with immunosuppression.³⁻⁵ For example, in the outpatient setting, therapeutic use of neutralizing antispike monoclonal antibody has been associated with decreases in the incidence of COVID-19-related disease progression and hospitalization. However, monoclonal antibody therapy is limited by the emergence of novel SARS-CoV-2 variants that have serially escaped neutralization.^{7,8} Thus, although monoclonal antibody therapy as a cornerstone of COVID-19 treatment, at the time of this writing, there are no US FDA approved monoclonal antibodies for the treatment or prevention of SARS-CoV-2 infection. However, high-titer COVID-19 convalescent plasma continues to be effective against SARS-CoV-2 variants of concern (VOCs) because of its broad-spectrum immunomodulatory properties and ability to neutralize multiple SARS-CoV-2 variants. 9,10 Although COVID-19 convalescent plasma is authorized for therapeutic use among patients with immunosuppression in the US and recommended by some organizations 11,12, its use remains controversial.4

COVID-19 convalescent plasma collected from persons who have been both naturally infected with SARS-CoV-2 and vaccinated against SARS-CoV-2 (herein referred to as "vax-plasma" and also known as vaccine-boosted convalescent plasma) is particularly high titer, typically containing 10 to 100 times higher anti-SARS-CoV-2 antibody titers than standard COVID-19 convalescent plasma. To further our understanding of the clinical impact associated with vax-plasma, we report the clinical outcome of 386 immunocompromised outpatients who were diagnosed with COVID-19 and treated with contemporary COVID-19 specific therapeutics (standard of care group) and a subgroup who also received treatment with vax-plasma or high-titer COVID-19 convalescent plasma and (vax-plasma group) with a specific focus on hospitalization rates.

Study design

- This large, observational cohort study included data from a single health system (Mayo Clinic)
- and represented data from multiple health care sites across Minnesota and Wisconsin from 1
- 64 December 2022 to 1 December 2023. Immunocompromised patients with active COVID-19
- 65 infection, confirmed by SARS-CoV-2-specific reverse transcription polymerase chain reaction,
- 66 were eligible to receive vax-plasma. The Mayo Clinic Institutional Review Board determined

- 67 that this study met the criteria for exemption. Informed consent was waived. Only Mayo Clinic
- patients with research authorization were included.
- As previously described¹⁷, eligible vax-plasma donors included individuals who had a confirmed
- 70 diagnosis of COVID-19 and had received at least one dose of a SARS-CoV-2 vaccine. All donors
- 71 experienced mild to moderate symptoms and met the national blood donor selection criteria.
- 72 Vax-plasma was collected at least 10 days and up to 6 months after the complete resolution of
- 73 COVID-19 symptomatology. Antibody titers of vax-plasma units met the minimum threshold
- 74 required by the US FDA for high titer anti-SARS-CoV-2 antibodies, but precise antibody titers
- 75 were not evaluated. However, numerous reports indicate that vax-plasma is uniformly
- 76 extremely high titer with neutralizing activity against many SARS-CoV-2 variants^{10,13,18}. The
- 77 treatment schedule of vax-plasma transfusions was not standardized. Patients received the
- 78 number of vax-plasma units deemed appropriate for each patient by their clinicians (range, 1 to
- 79 7 units).
- 80 The primary outcome was COVID-19-related hospitalization within 28 days after transfusion,
- assessed as the cumulative incidence in the vax-plasma group compared to the standard of care
- 82 group who declined treatment vax-plasma. The decision to hospitalize patients was at the
- 83 discretion of local clinicians. Continuous measures were compared between the treatment
- 84 groups (vax-plasma group vs. standard of care group) using the two-sample t-test, whereas
- 85 categorical measures were compared using the χ^2 test or Fisher exact test, as appropriate.
- 86 Reported p-values are two-sided and adjusted for multiplicity, as appropriate; and the
- interpretation of findings was based on p < 0.05.

Results and discussion

- 89 Three-hundred eighty-six immunocompromised patients were offered standard of care
- 90 treatments (e.g., remdesivir, nirmatrelvir or molnupiravir) and were also offered to be treated
- 91 with vax-plasma. Of those patients, 58% agreed to treatment with vax-plasma (225 of 386
- 92 patients; vax-plasma group) and 42% (161 of 386 patients) received standard of care
- 93 treatments alone without vax-plasma (standard of care group). Key demographic and clinical
- characteristics of the study population are provided in **Table 1**, stratified into the two treatment
- groups. Overall, the median age of all patients was 66 years (range: 2 to 96 years), 45% were
- 96 female (175 of 386 patients), and 94% (361 of 386 patients) were vaccinated against SARS-CoV-
- 97 2.

88

- 98 Compared to patients in the standard of care group, patients in the vax-plasma group were
- 99 more likely to be female (P=0.038), more likely to have received anti-CD20 monoclonal therapy
- 100 (P=0.028), and more likely to have received previous COVID-19 antiviral treatments (P<0.001).
- 101 Other key differences between the groups are noted in **Table 1**.

Patients had COVID-19 symptoms for a median of 5 days (range, 1 to 46 days) before receiving vax-plasma, and the median number of units transfused per patient was 1 (range, 1 to 7 units of vax-plasma). Most patients (73%, 281 of 386 patients) agreed to receive concomitant COVID-19—specific treatments, and patients in the vax-plasma group were more likely to have received COVID-19 specific treatments (88%, 198 of 225 patients) compared to the standard of care group (52%, 83 of 161 patients; *P*<0.001). COVID-19 specific treatments included remdesivir (65% of patients who accepted vax-plasma and 32% of those who declined vax-plasma), nirmatrelvir and ritonavir (PAXLOVID™) (28% in the vax-plasma group and 20% in the standard of care group), and/or molnupiravir (1% in the vax-plasma group and 4% in the standard of care group).

- No major adverse effects were recorded among patients transfused with vax-plasma. The overall 28 day-hospital admission rate was 2.2% (5 of 225 patients) in vax-plasma group and
- 114 6.2% (10 of 161 patients) in standard of care group (*P*=0.046).

- In this large, non-randomized cohort study involving outpatients with recent SARS-CoV-2 infection, the concomitant administration of high-titer COVID-19 convalescent plasma in addition to standard of care therapeutics was associated with a decreased incidence of hospitalization. Our observations are consistent with those of previous trials of antibody-based therapies —administration of sufficient pathogen-specific antibodies via COVID-19 convalescent plasma leads to a reduced risk of disease progression, COVID-19-related hospitalization, and COVID-19-related death in immunocompromised patients in both outpatient and inpatient settings.^{5,19} Collectively, contemporary clinical data provide evidence to support the utility of high-titer convalescent plasma including vax-plasma as antibody replacement therapy in immunocompromised patients.^{17,20,21}
 - There is consensus that the primary mechanism of action of vax-plasma is through viral neutralization¹⁹—a finding established among humans early during the COVID-19 pandemic²² and supported by several preclinical models including mice, ^{23,24} hamsters, ²⁵ and macaques. ²⁶ Because the neutralizing capacity of vax-plasma can evolve with emerging variants, issues related to escape by new variants that have time limited the efficacy of monoclonal antibodies can potentially be avoided. Additionally, sero-surveys of blood donors show a high prevalence of hybrid immunity in the population suggesting that very high titer vax-plasma is potentially available at a scale sufficient to treat immunocompromised patients. ²⁷ Thus, there is an emerging picture of utility for vax-plasma therapy in immunocompromised patients with SARS-CoV-2 infection that could benefit from further evaluation via carefully matched, larger real world data sets. Importantly, any prospective studies will need to consider the experimental design and ethical issues associated with potentially limiting a safe antibody therapy in

immunocompromised patients unable to generate an adequate endogenous antibody response to infection.

Our study faced several contextual challenges associated with clinical research during a pandemic and limitations associated with the design of the study. First, the interpretation of these results is limited by the open-label and non-randomized design. In this framework, the vax-plasma group had higher rates of anti-CD20 monoclonal therapy, antiviral COVID-19-specific therapeutics, and vaccination against SARS-CoV-2. Importantly, treatment with anti-CD20 monoclonal therapy among people who are immunosuppressed is associated with the lowest likelihood to produce SARS-CoV-2 antibodies after one or more doses of COVID-19 vaccines. This, the effects of vax-plasma per se may not be definitively inferred. Second, the overall incidence of hospitalization was very low (3.8%, 15 of 386 patients), likely due in part to the very high number of patients who were vaccinated against SARS-CoV-2 and because most patients received standard of care COVID-19-specific therapeutics. In this context, the low incidence of the primary outcome (COVID-19-related hospitalization) limited the potential for definitive subgroup analyses according to coexisting immunosuppressive conditions or other putative confounding variables. Third, SARS-CoV-2 serology of vax-plasma units or patient samples was not systematically performed.

Despite the enumerated limitations of this study, our data provides evidence that transfusion of vax-plasma effectively transfers COVID-19-neutralizing antibodies to patients with immunosuppression and reduces the risk of COVID-19-related hospitalization. Vax-plasma appears to be an effective therapeutic throughout the clinical course of COVID-19 among immunocompromised patients from outpatients to inpatients with protracted COVID-19. For future pandemics, the use of therapeutic plasma with antibody levels in the upper deciles should be considered, particularly among immunocompromised patients.

Acknowledgments

We thank the dedicated members of the Mayo Clinic Blood Donor Center for their rigorous efforts necessary to make this program possible. We also thank the donors who survived COVID-19 for providing vaccine-boosted COVID-19 convalescent plasma. Additionally, we thank Diana Zicklin Berrent and Chaim Lebovits for their progressive and passionate patient advocacy and support.

This work was supported by United Health Group and Mayo Clinic.

Authorship Contributions

Study conception and design: J.G.R., S.M.T-S, M.J.J., and J.W.S. Acquisition, analysis, or interpretation of data: J.G.R., S.M.T-S, A.A.S., S.F., M.L.P., E.K.G., A.J.M., S.Z., E.A.O., and J.W.S. Drafting of the manuscript: J.G.R., S.M.T-S, M.J.J., and J.W.S. Administrative, technical, or material support: S.N.H., J.E.J., R.R.R., R.G., R.T.H., E.N.F., A.N.D., M.R.E., J.J.L., C.M.C., E.S.T., S.A.P., and N.E.K. All authors contributed to revising the manuscript, and all authors approved the final version of the manuscript.

Disclosure of Conflicts of interest

The authors declare no conflict of interest.

Data Availability

Datasets generated during this study may be available from corresponding authors on reasonable request. Requestors may be required to sign a data use agreement. Data sharing must be compliant with all applicable Mayo Clinic policies and those of the Mayo Clinic Institutional Review Board.

ORCID

https://orcid.org/0000-0003-4908-9774 Juan G. Ripoll https://orcid.org/0000-0003-2776-9023 Shane Ford https://orcid.org/0000-0003-2989-547X Ellen K. Gorman https://orcid.org/0000-0002-7868-2852 Justin E. Juskewitch Alexander J. Miller https://orcid.org/0009-0006-2814-5561 https://orcid.org/0009-0006-3030-7232 Solomiia Zaremba Erik A. Ovrom https://orcid.org/0000-0002-5661-0698 https://orcid.org/0000-0001-5248-0227 Raymund R. Razonable Ravindra Ganesh https://orcid.org/0000-0002-6877-1712 https://orcid.org/0000-0002-6886-2294 Elitza S. Theel Sameer A. Parikh https://orcid.org/0000-0002-3221-7314 https://orcid.org/0000-0002-5951-5055 Neil E. Kay Michael J. Joyner https://orcid.org/0000-0002-7135-7643 Jonathon W. Senefeld https://orcid.org/0000-0001-8116-3538

References

- 1. Fendler A, de Vries EGE, GeurtsvanKessel CH, et al. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. *Nat Rev Clin Oncol*. 2022;19(6):385-401.
- 2. Ribas A, Dhodapkar MV, Campbell KM, et al. How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies. *Blood Cancer Discov.* 2021;2(6):562-567.
- 3. Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. *Nature Reviews Immunology*. 2021;21(6):382-393.
- 4. Shoham S, Batista C, Ben Amor Y, et al. Vaccines and therapeutics for immunocompromised patients with COVID-19. *eClinicalMedicine*. 2023;59:101965.
- 5. Senefeld JW, Franchini M, Mengoli C, et al. COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis. *JAMA Netw Open*. 2023;6(1):e2250647.
- 6. Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal antibody therapies against SARS-CoV-2. *Lancet Infect Dis.* 2022;22(11):e311-e326.
- 7. Focosi D, Maggi F, Franchini M, McConnell S, Casadevall A. Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review. *Int J Mol Sci.* 2021;23(1).
- 8. VanBlargan LA, Errico JM, Halfmann PJ, et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. *Nat Med*. 2022;28(3):490-495.
- 9. Senefeld JW, Klassen SA, Ford SK, et al. Use of convalescent plasma in COVID-19 patients with immunosuppression. *Transfusion*. 2021;61(8):2503-2511.
- 10. Li M, Beck EJ, Laeyendecker O, et al. Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern. *Blood Adv.* 2022;6(12):3678-3683.
- 11. Estcourt LJ, Cohn CS, Pagano MB, et al. Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma. *Ann Intern Med*. 2022;175(9):1310-1321.
- 12. Cesaro S, Ljungman P, Mikulska M, et al. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). *Leukemia*. 2022;36(6):1467-1480.
- 13. Schmidt F, Weisblum Y, Rutkowska M, et al. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. *Nature*. 2021;600(7889):512-516.
- 14. Hueso T, Pouderoux C, Péré H, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. *Blood*. 2020;136(20):2290-2295.
- 15. Thompson MA, Henderson JP, Shah PK, et al. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. *JAMA Oncol*. 2021;7(8):1167-1175.
- 16. Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. *Cancer Cell*. 2021;39(8):1031-1033.

- 17. Ripoll JG, Gorman EK, Juskewitch JE, et al. Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19. *Blood Adv.* 2022;6(23):5951-5955.
- 18. Callaway E. COVID super-immunity: one of the pandemic's great puzzles. *Nature*. 2021;598(7881):393-394.
- 19. Casadevall A, Joyner MJ, Pirofski LA, et al. Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy. *Expert Rev Respir Med*. 2023;17(5):381-395.
- 20. Senefeld JW, Joyner MJ. SARS-CoV-2 Antibody Replacement Therapy for Immunocompromised Patients. *Clin Infect Dis.* 2023.
- 21. Upasani V, Townsend K, Wu MY, et al. Commercial immunoglobulin products contain neutralising antibodies against SARS-CoV-2 spike protein. *Clin Infect Dis.* 2023.
- 22. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc Natl Acad Sci U S A*. 2020;117(17):9490-9496.
- 23. Golden JW, Zeng X, Cline CR, et al. Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease. *J Gen Virol*. 2021;102(5).
- 24. Zheng J, Wong LR, Li K, et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. *Nature*. 2021;589(7843):603-607.
- 25. Haagmans BL, Noack D, Okba NMA, et al. SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model. *J Infect Dis.* 2021;223(12):2020-2028.
- 26. McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. *Nature*. 2021;590(7847):630-634.
- 27. Focosi D, Meschi S, Coen S, et al. Serum anti-Spike immunoglobulin G levels in random blood donors in Italy: High-titre convalescent plasma is easier than ever to procure. *Vox Sang*. 2023.
- 28. Pearce FA, Lim SH, Bythell M, et al. Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY. *Lancet Rheumatol.* 2023;5(8):e461-e473.

Table 1. Characteristics of 386 immunocompromised outpatients who were diagnosed with COVID-19 and received standard of care COVID-19 therapeutics with or without vax-plasma.

	Vax-plasma, N = 225	SOC, N = 161	P value
Demographic information			
Age, median (range), years	66 (2-93)	64 (20-96)	0.468
Females/males, n	112/113	63/98	0.038
Height, median (range), cm	172.5 (85.3-195.0)	173.0 (146.2-197.4)	0.440
Weight, median (range), kg	82.7 (12.4-176.0)	81.5 (44.6-210.0)	0.691
Body Mass Index, median (range), kg·m ⁻²	28.1 (17.0-54.1)	27.6 (18.2-63.7)	0.952
Hematological malignancies, n (%)			
Multiple Myeloma	30 (13)	38 (24)	0.009
Chronic lymphocytic leukemia	43 (19)	20 (12)	0.080
Diffuse large B-cell lymphoma	20 (9)	23 (14)	0.097
Follicular lymphoma	15 (7)	4 (2)	0.061
Other malignancy ^a	57 (25)	45 (28)	0.331
Other immunosuppressive conditions, n (%)			
Multiple sclerosis	25 (11)	6 (4)	0.008
Solid organ transplant⁵	13 (6)	13 (8)	0.375
Common variable immune deficiency	3 (1)	5 (3)	0.228
Granulomatosis with Polyangiitis	5 (2)	4 (2)	0.866
Other immunosuppressive conditions ^c	17 (8)	9 (6)	0.447
Active immunosuppressive treatment, n (%)			
Anti-CD20 therapy	78 (35)	39 (24)	0.028
Anti-CD38 therapy	15 (7)	11 (7)	0.949
Bruton tyrosine kinase inhibitors	22 (10)	11 (7)	0.307
Previous COVID-19-specific treatments, n (%)	198 (88)	83 (52)	<0.001
Remdesivir	146 (65)	52 (32)	<0.001
Paxlovid	62 (28)	33 (20)	0.112
Molnupiravir	3 (1)	6 (4)	0.124
Vaccinated against SARS-CoV-2, n (%)	214 (95)	147 (91)	0.134
Number of SARS-CoV-2 vaccines ^d , mean (SD), n	3.8 (1.6)	3.7 (1.2)	0.504
Units of vax-plasma, median (range), n	1 (1-7)		
Time to treatment, median (range), days	5 (1-46)		
Hospital admission, n (%)	5 (2.2)	10 (6.2)	0.046

Footnotes

Note that hematological malignancies and other immunosuppressive conditions are not mutually exclusive.

^aOther malignancies included acute lymphoblastic leukemia (ALL, n=5); acute myeloid leukemia (AML, n=7); anaplastic large cell lymphoma (N=1); angioimmunoblastic T-cell Lymphoma (n=1); chronic lymphoproliferative disorder of natural killer cells (CLPD-NK, n=1); chronic myeloid leukemia (CML, n=8); chronic myelomonocytic leukemia (CMML, n=1); cutaneous B-cell lymphoma (n=1)Dermatomyositis (n=1); duodenal adenocarcinoma (n=1); gastroesophageal junction adenocarcinoma (n=1); Hairy Cell Leukemia (n=1); hodgkin lymphoma (HL, n=11); large granular lymphocytic leukemia (n=1); lung adenocarcinoma (n=3); MALT Lymphoma (n=1); mantle cell lymphoma (MCL, n=8); marginal zone lymphoma (MZL, n=12); Metastatic Carcinoid Tumor (n=1); Metastatic Melanoma (n=1); monoclonal gammopathy of undetermined significance (MGUS, n=5); myelodysplastic syndrome (MDS, n=8); Myelofibrosis (n=1); Polycythemia Vera (n=2); Prolymphocytic Leukemia (n=1); Testicular Cancer (n=1); non-Hodgkin lymphoma (n=1), and small lymphocytic lymphoma (n=1); Waldenstrom macroglobulinemia (WM, n=16).

^bSolid organ transplants included: kidney (n = 3); heart (n = 1); kidney and pancreas (n = 4); lung(s) (n = 11); lung and heart (n = 1); kidney and liver (n = 2); kidney and heart (n = 3); and heart, liver, and kidney (n = 1).

Other immunosuppressive conditions included: autoimmune lymphoproliferative syndrome (ALPS, n = 1); Amyloidosis (n = 2); ANCA Vasculitis (n = 2); autoimmune myositis (n = 2); HIV (n = 2); Immune Thrombocytopenic Purpura (ITP, n = 1); membranous nephropathy (MN, n = 1); minimal change disease (n = 1); Neuromyelitis Optica (n = 1); Rheumatoid Arthritis (RA, n = 6); Stiff-Person Syndrome (SPS, n = 1); systemic lupus erythematosus (SLE, n = 3); thrombotic thrombocytopenic purpura (TTP, n = 1); undifferented primary immunodeficiency (n = 1); and a constellation of comorbidities (seizure disorder, previous stroke, ventricular septal defect, prolonged QT interval, right bundle-branch block, congestive heart failure, chronic obstructive pulmonary disease; n = 1).

^dThe mean number of SARS-CoV-2 vaccines was calculated among people who have been vaccinated against SARS-CoV-2, including 214 patients in the vax-plasma group and 147 patients in the standard of care (SOC) group.